Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)

PURPOSE: Adjuvant FOLFOX is a widely accepted standard therapy for resected colon cancer. The incidence of grade 3–4 peripheral sensory neuropathy (PSN) was 12.4 and 5.7 % in the MOSAIC and Eastern MASCOT trials, while that of grade 3–4 allergic reactions (AR) was 2.9 and 3.1 %, respectively. The JF...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotaka, Masahito, Yoshino, Takayuki, Oba, Koji, Shinozaki, Katsunori, Touyama, Tetsuo, Manaka, Dai, Matsui, Takanori, Ishigure, Kiyoshi, Hasegawa, Junichi, Inoue, Keiji, Goto, Koichi, Sakamoto, Junichi, Saji, Shigetoyo, Ohtsu, Atsushi, Watanabe, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485846/
https://www.ncbi.nlm.nih.gov/pubmed/25983021
http://dx.doi.org/10.1007/s00280-015-2757-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485846/
https://www.ncbi.nlm.nih.gov/pubmed/25983021
http://dx.doi.org/10.1007/s00280-015-2757-0

Ejemplares similares